A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

Acute Lymphoblastic Leukemia Clinical Trial

— ALL-RIC  

Official title:

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03821610
• Other study ID #: RG_17-241
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: November 22, 2018
• Est. completion date: November 22, 2027

Study information

• Verified date: May 2024
• Source: University of Birmingham
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The current national acute lymphoblastic leukaemia (ALL) trial in adults investigated whether a low (reduced) intensity chemotherapy regimen prior to transplant could improve the outcome of patients with ALL who are over 40 years of age. The results (60% 2 year survival) are very encouraging but patients who come to transplant with small amounts of 'residual' disease had less good outcomes. The goal of this trial is to see if a slightly stronger chemotherapy regimen (involving total body irradiation, (TBI)) can improve results by reducing the chance of the disease coming back (relapsing) without increasing the chance of not surviving the transplant. Up to 242 patients will be 'randomised' to the trial to receive either the established chemotherapy of fludarabine and melphalan or cyclophosphamide and TBI to compare the outcomes between the two treatment regimens. Other measures to reduce relapse will be the earlier use of donor white cell infusions and earlier stopping of immune suppressive drugs to enhance the immune effect of the transplanted cells (graft). Patients will be followed up for a minimum of 3 years. All patients on the next national ALL trial (UKALL XV) will be offered this trial but it will also be open to patients not on this study.

Description:

TRIAL SYNOPSIS

Trial Design This is a 2 arm, phase II, multicentre, randomised clinical trial in adult patients with ALL in complete remission (CR) undergoing allogeneic stem cell transplantation (SCT) comparing the novel conditioning regimen of TBI and cyclophosphamide with the standard condition of Fludarabine/Melphalan/Alemtuzumab (FMA).

Patient will be stratified at randomisation by the donor type (sibling; suitable matched), CR status (CR1; CR2) and by age (above; below 55 years of age). Patients eligible for entry into the trial will be randomised on a 1:1 basis to receive either the experimental treatment arm or the control arm.

Objectives Primary Objectives To compare the disease free survival (DFS) at two years of patients with ALL after a TBI and cyclophosphamide allograft with that of patients transplanted using the FMA conditioning regimen.

Secondary Objectives To compare overall survival (OS), cumulative incidence of disease relapse (CIR), non-relapse mortality (NRM), incidence of grade 2-4 acute graft-versus-host-disease (GvHD), incidence of chronic GvHD of any grade, occurrence and severity of veno-occlusive disease (VOD), duration of hospitalisation in the first year, quality of life (QoL), full donor chimerism at day 100 and TBI related symptomatic pulmonary toxicity between the control and experimental arm following allogenic SCT.

Exploratory Objectives To measure multi-lineage chimerism and molecular minimal residual disease (MRD) at 3 monthly intervals and the ability of planned donor lymphocyte infusion (DLI) to 'correct' mixed chimerism and reverse molecular relapse/persistence and reduce the incidence of frank haematologic relapse.

To ascertain if either of the conditioning arms is more effective in controlling disease in patients who are MRD positive before transplant.

Patient Population This trial will recruit patients with ALL in CR as defined by the WHO classification (Appendix 1). Patients enrolled onto the UKALL XIV registration study and the planned national UKALL XV study who are eligible for transplant will also be able to enrol onto ALL-RIC provided they meet the entry criteria.

Sample Size A minimum of 247 patients will be randomised 1:1 between the control and experimental treatment arms.

Trial Duration Patients will be recruited over 48 months across IMPACT centres. Patients will be followed up for a minimum of 5 years.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 242
• Est. completion date: November 22, 2027
• Est. primary completion date: November 22, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients between the ages of 40-70 years. NB: Patients under the age of 40 who are considered unsuitable for a myeloablative transplant may enrol onto the trial following discussion with the CI via the Trials Office

• Patients with ALL in first or second CR

• Availability of a human leukocyte antigen (HLA) identical sibling or suitable matched donor (suitable matched defined as no greater than a single allele mismatch at HLA A, B, C or DRß1). A single allele mismatch is permitted if there are adverse cytogenetics or MRD positivity at any timepoint

• Patients considered suitable to undergo a RIC allogeneic SCT as clinically judged by the Local Investigator including:-

• Adequate hepatic and renal function as determined by full blood count and biochemistry assessment

• Resolution of any toxic effects of prior therapy (including radiotherapy, chemotherapy or surgical procedures). Patients with bone marrow suppression following therapy may enter the trial

• Patients with abnormal cardiac and/or pulmonary function must be considered fit for allogeneic SCT including 8Gy of TBI at the time of randomisation.

• Patients with an ECOG performance status 0,1 or 2

• Females of and male patients of reproductive potential (i.e., not post-menopausal or surgically sterilised) must use appropriate, highly effective, contraception from the point of admission for transplant conditioning therapy until 12 months after transplant (see section 8.1.2.2)

• Patients have given written informed consent

• Patients willing and able to comply with scheduled study visits and laboratory tests

Exclusion Criteria:

• Patients with contraindications to receiving RIC allogeneic SCT

• Female patients who are pregnant or breastfeeding. All women of childbearing potential (WOCBP) must have a negative pregnancy test before commencing treatment

• Adults of reproductive potential not willing to use appropriate, effective, contraception during the specified period

• Patients with renal or hepatic impairment as clinically judged by Local Investigator

• Patients with active infection, HIV-positive or chronic active Hep-A or -C

• Patients with concurrent active malignancy. Patients with a previous history of malignancy can be included if that malignancy is considered to be at a low risk of recurrence

• Previous exposure to a high dose of radiotherapy

Related Conditions & MeSH terms

• Acute Lymphoblastic Leukemia
• Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Drug:
• Fludarabine
IV
• Melphalan
IV
• Alemtuzumab
IV
• Cyclophosphamide
IV
• Mesna
IV

Radiation:
• Total Body Irradiation (8Gy)
TBI (8Gy)

Locations

Country	Name	City	State
United Kingdom	Heart of England Nhs Foundation Trust	Birmingham
United Kingdom	University Hospitals Birmingham Nhs Foundation Trust	Birmingham
United Kingdom	University Hospitals Bristol Nhs Foundation Trust	Bristol
United Kingdom	Cambridge University Hospitals Nhs Foundation Trust	Cambridge
United Kingdom	Cardiff and Vale University Health Board	Cardiff
United Kingdom	NHS Greater Glasgow and Clyde	Glasgow
United Kingdom	Leeds Teaching Hospitals Nhs Trust	Leeds
United Kingdom	University Hospitals of Leicester Nhs Trust	Leicester
United Kingdom	The Clatterbridge Cancer Centre Nhs Foundation Trust	Liverpool
United Kingdom	Barts Health Nhs Trust	London
United Kingdom	Imperial College Healthcare Nhs Trust	London
United Kingdom	Kings College Hospital	London
United Kingdom	The Royal Marsden Nhs Foundation Trust	London
United Kingdom	University College London Hospitals Nhs Foundation Trust	London
United Kingdom	Central Manchester University Hospitals Nhs Foundation Trust	Manchester
United Kingdom	The Christie Nhs Foundation Trust	Manchester
United Kingdom	The Newcastle Upon Tyne Hospitals Nhs Foundation Trust	Newcastle
United Kingdom	Nottingham University Hospitals Nhs Trust	Nottingham
United Kingdom	Oxford University Hospitals Nhs Foundation Trust	Oxford
United Kingdom	Plymouth Hospitals Nhs Trust	Plymouth
United Kingdom	Sheffield Teaching Hospitals Nhs Foundation Trust	Sheffield
United Kingdom	University Hospital Southampton Nhs Foundation Trust	Southampton

Sponsors (1)

Lead Sponsor	Collaborator
University of Birmingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Correlation of multi-lineage chimerism and relapse		The main analysis will take place once all patients have completed 2 years of follow up. A subsequent analysis of long terms outcomes will be completed when all patients have completed 5 years of follow up
Other	Correlation of Minimal Residual Disease (MRD) with relapse		The main analysis will take place once all patients have completed 2 years of follow up. A subsequent analysis of long terms outcomes will be completed when all patients have completed 5 years of follow up
Primary	Disease Free Survival (DFS)	Defined as time from randomisation to the first of relapse or death from any cause. Patients who are still alive and progression free at the end of the trial will be censored at their last date known to be alive.	The main analysis will take place once all patients have completed 2 years of follow up.
Secondary	Overall Survival (OS)	Defined as time from randomisation to date of death from any cause. Patients who are alive at the end of the trial will be censored at their date last known to be alive	The main analysis will take place once all patients have completed 2 years of follow up. A subsequent analysis of long terms outcomes will be completed when all patients have completed 5 years of follow up
Secondary	Cumulative Incidence of Relapse (CIR)	Defined as time from randomisation to the date of relapse. Patients who die without relapse will be treated as a competing risk and patients who are alive and relapse free at the end of the trial will be censored as their date last seen	The main analysis will take place once all patients have completed 2 years of follow up. A subsequent analysis of long terms outcomes will be completed when all patients have completed 5 years of follow up
Secondary	Non-relapse mortality (NRM)	Defined as time from randomisation to death from any cause that occurred without relapse. Patients who relapse will be treated as a competing risk and patients who are still alive and relapse free at the end of the trial will be censored at their date last known to be aliveIncidence of Grade 2-4 acute GvHD within 100 days of transplant	The main analysis will take place once all patients have completed 2 years of follow up. A subsequent analysis of long terms outcomes will be completed when all patients have completed 5 years of follow up
Secondary	Incidence of chronic GvHD of any grade at 2 years		The main analysis will take place once all patients have completed 2 years of follow up. A subsequent analysis of long terms outcomes will be completed when all patients have completed 5 years of follow up
Secondary	Occurrence and severity of VOD (Veno-occlusive disease) in the first 100 days		The main analysis will take place once all patients have completed 2 years of follow up. A subsequent analysis of long terms outcomes will be completed when all patients have completed 5 years of follow up
Secondary	Duration of hospitalisation	Duration of hospitalisation recorded between start of conditioning regimen and 1 year post transplantation.	The outcome will be conducted when all patients have completed 1 year of follow up.
Secondary	Quality of Life (QoL) assessment (FACT-BMT Questionnaire)	FACT-BMT Questionnaire uses Units on a scale 0-4. It measures quality of life, with 0 being the lowest quality of life and 4 being the highest quality of life.	Collected at baseline, Day 100, Month 12, Month 24, Month 36, Month 48 and Month 60 for each patient. The outcome will be analysed when the last patient has completed 2 years of follow up.
Secondary	Quality of Life (QoL) assessment (Short Form 36 Health Survey)	Short Form 36 Health Survey uses Units on a scale 1-6. Question 1 & 2 consider general health (1 = best health score, 5 = worst). Question 3 considers activity level (1= least active, 3 = most). Question 4/5 considers work (1= work affected, 2= work not affected). Question 6 considers quality of relationships (1=not affected, 5 = most affected). Question 7 considers pain (1= no pain, 6 = worst). Question 8 considers housework/ paid work (1= not affected, 5= most affected). Question 9 considers mental health (1= best mental health, 6= worst). Question 10 considers social activities (1=most affected, 5= least affected). Question 11 considers self perception (1= worst, 5= best)	Collected at baseline, Day 100, Month 12, Month 24, Month 36, Month 48 and Month 60 for each patient. The outcome will be analysed when the last patient has completed 2 years of follow up.
Secondary	Full donor chimerism	Number of patients with full donor chimerism at day 100 Follow Up (for each patient)	The outcome will be analysed when all patients have completed 100 days follow up.
Secondary	Occurrence and severity of TBI related symptomatic pulmonary toxicity	Collected using CTCAE 4.0 criteria	Collected in first 12 months from start of treatment